UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 97

Sortiert nach

Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial

The lancet oncology, 2014-11, Vol.15 (12), p.1351-1360

2014

Link zum Volltext

Verfügbarkeit prüfen

Practical considerations for expediting breast cancer treatment in Brazil

Lancet Regional Health - Americas (Online), 2021-10, Vol.2, p.100028-100028, Article 100028

2021

Link zum Volltext

Verfügbarkeit prüfen

Nuclear and Cytoplasmic hTERT, Tumor-Infiltrating Lymphocytes, and Telomere Elongation Leukocytes Are Independent Factors in the Response to Neoadjuvant Treatment in HER2-Enriched Breast Cancer

Current oncology (Toronto), 2023-04, Vol.30 (4), p.4094-4109

2023

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant Treatment of Stage IIB/III Triple Negative Breast Cancer with Cyclophosphamide, Doxorubicin, and Cisplatin (CAP Regimen): A Single Arm, Single Center Phase II Study (GBECAM 2008/02)

Frontiers in oncology, 2018-01, Vol.7, p.329-329

2018

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up

Journal of clinical oncology, 2021-05, Vol.39 (13), p.1448-1457

2021

Link zum Volltext

Verfügbarkeit prüfen

Multidisciplinary Approach to Neoadjuvant Endocrine Therapy in Breast Cancer: A Comprehensive Review

Revista Brasileira de ginecologia e obstetrícia, 2016-12, Vol.38 (12), p.615-622

2016

Link zum Volltext

Verfügbarkeit prüfen

Real-World Evidence of Ribociclib Plus Aromatase Inhibitors as First-Line Treatment in Advanced Breast Cancer: The BrasiLEEira Study

JCO global oncology, 2024-04, Vol.10 (10), p.e2300484-e2300484

2024

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients

JNCI : Journal of the National Cancer Institute, 2019-01, Vol.111 (1), p.86-94

2019

Link zum Volltext

Verfügbarkeit prüfen

Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer

Frontiers in oncology, 2017-03, Vol.7, p.26-26

2017

Link zum Volltext

Verfügbarkeit prüfen

Cell free DNA biology and its involvement in breast carcinogenesis

Advances in clinical chemistry, 2020, Vol.97, p.171

2020

Link zum Volltext

Verfügbarkeit prüfen

Implications of ESR1 Mutations in Hormone Receptor-Positive Breast Cancer

Current treatment options in oncology, 2018-05, Vol.19 (5), p.24-13, Article 24

2018

Link zum Volltext

Verfügbarkeit prüfen

Time interval between diagnosis to treatment of breast cancer and the impact of health insurance coverage: a sub analysis of the AMAZONA III Study (GBECAM 0115)

Breast cancer research and treatment, 2023-02, Vol.198 (1), p.123-130

2023

Link zum Volltext

Verfügbarkeit prüfen

Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

Clinical cancer research, 2023-01, Vol.29 (2), p.389-400

2023

Link zum Volltext

Verfügbarkeit prüfen

Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer

British journal of cancer, 2021-07, Vol.125 (1), p.38-47

2021

Link zum Volltext

Verfügbarkeit prüfen

The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115)

Breast cancer research and treatment, 2020-10, Vol.183 (3), p.749-757

2020

Link zum Volltext

Verfügbarkeit prüfen

Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT

Journal of clinical oncology, 2008-04, Vol.26 (10), p.1664-1670

2008

Link zum Volltext

Verfügbarkeit prüfen

Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer

Journal of clinical oncology, 2008-12, Vol.26 (34), p.5544-5552

2008

Link zum Volltext

Verfügbarkeit prüfen

Abstract PS11-23: Current landscape in phase 3 trials in breast cancer at major oncology conferences

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS11-23-PS11-23

2021

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of Breast Cancer in Brazil Related to Health Care Coverage: A Retrospective Cohort Study

Cancer epidemiology, biomarkers & prevention, 2014, Vol.23 (1), p.126-133

2014

Link zum Volltext

Verfügbarkeit prüfen

Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

Clinical breast cancer, 2020-04, Vol.20 (2), p.174-181.e3

2020

Link zum Volltext

Verfügbarkeit prüfen

Breast cancer-associated venous thromboembolism: A case–control study

Breast (Edinburgh), 2016-08, Vol.28, p.84-88

2016

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic and exploratory exposure–response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study

Cancer chemotherapy and pharmacology, 2019-06, Vol.83 (6), p.1147-1158

2019

Link zum Volltext

Verfügbarkeit prüfen

Anthracyclines and taxanes in the neo/adjuvant treatment of breast cancer: does the sequence matter?

Annals of oncology, 2014-06, Vol.25 (6), p.1079-1085

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 97

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(90)
Mit Volltextzugriff
(91)

Publikationsform

Sprache

Englisch
(97)
Portugiesisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Cancer Research
(14)
Journal Of Clinical Oncology
(14)
Cancer
(9)
Breast Cancer Research And Treatment
(4)
Clinical Breast Cancer
(4)
Frontiers In Oncology
(3)
The Breast Journal
(3)
The Oncologist
(3)
Brazilian Journal Of Oncology
(2)
Breast
(2)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial

Practical considerations for expediting breast cancer treatment in Brazil

Nuclear and Cytoplasmic hTERT, Tumor-Infiltrating Lymphocytes, and Telomere Elongation Leukocytes Are Independent Factors in the Response to Neoadjuvant Treatment in HER2-Enriched Breast Cancer

Neoadjuvant Treatment of Stage IIB/III Triple Negative Breast Cancer with Cyclophosphamide, Doxorubicin, and Cisplatin (CAP Regimen): A Single Arm, Single Center Phase II Study (GBECAM 2008/02)

ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor-Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up

Multidisciplinary Approach to Neoadjuvant Endocrine Therapy in Breast Cancer: A Comprehensive Review

Real-World Evidence of Ribociclib Plus Aromatase Inhibitors as First-Line Treatment in Advanced Breast Cancer: The BrasiLEEira Study

Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients

Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer

Cell free DNA biology and its involvement in breast carcinogenesis

Implications of ESR1 Mutations in Hormone Receptor-Positive Breast Cancer

Time interval between diagnosis to treatment of breast cancer and the impact of health insurance coverage: a sub analysis of the AMAZONA III Study (GBECAM 0115)

Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer

Characteristics and prognosis of stage I-III breast cancer subtypes in Brazil: The AMAZONA retrospective cohort study

The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115)

Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT

Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer

Abstract PS11-23: Current landscape in phase 3 trials in breast cancer at major oncology conferences

Outcomes of Breast Cancer in Brazil Related to Health Care Coverage: A Retrospective Cohort Study

Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

Breast cancer-associated venous thromboembolism: A case–control study

Pharmacokinetic and exploratory exposure–response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study

Anthracyclines and taxanes in the neo/adjuvant treatment of breast cancer: does the sequence matter?

Suchergebnisse filtern